istradefylline

Known as: 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione 
 

Topic mentions per year

Topic mentions per year

2003-2017
051020032017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Kyowa Hakko Kirin is developing istradefylline, a selective adenosine A2A receptor antagonist, for the once-daily oral treatment… (More)
Is this relevant?
2013
2013
BACKGROUND We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as… (More)
  • table 1
  • table 2
Is this relevant?
2013
2013
Adenosine A2A receptors are suggested to be a promising non-dopaminergic target for the treatment of Parkinson’s disease (PD… (More)
  • table 1
  • table 2
  • table 2
  • table 3
  • figure 1
Is this relevant?
2012
2012
BACKGROUND Istradefylline (KW-6002) is a selective adenosine A(2A) receptor antagonist investigated as adjunctive therapy to… (More)
Is this relevant?
2010
2010
OBJECTIVE 6002-US-051 was a 12-week, double-blind study evaluating the safety and efficacy of istradefylline, a selective A(2A… (More)
Is this relevant?
2010
2010
The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose of 20 mg or 40 mg once daily for 12… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND The safety and efficacy of istradefylline, a selective adenosine A(2A) receptor antagonist, was evaluated in a 12-week… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
OBJECTIVE Based on new understanding of nondopaminergic pathways involved in Parkinson's disease (PD) pathophysiology, a… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
OBJECTIVE To evaluate the safety and efficacy of the adenosine A(2A) receptor antagonist istradefylline (KW-6002) in patients… (More)
Is this relevant?